Bağırsak Mikrobiyatası, Probiyotikler ve İrritable Bağırsak Sendromu(İBS)

Abstract

İrritable bağırsak sendromu (İBS), karın ağrısı, rahatsızlık hissi ve bağırsakalışkanlıklarının değişmesi gibi belirtilerle karakterize kompleks bir hastalıktır.Son deneysel ve klinik araştırmalara dayanarak, düşük dereceli inflamasyon, değiştirilmiş bağırsak mikrobiyatası ve bağırsak bağışıklık sistemindeki değişikliği içermektedir.Bu etiyolojik faktörlerin İBS patogenezinde önemli rol oynadığı öne sürülmüştür.

Bu nedenle, değişmiş bağırsak mikrobiyotiklerinin terapötik restorasyonu İBS için ideal bir tedavi olabilir.Temel bağırsak hastalıkları üzerine bağırsak mikrobiyatası hakkında çok az veri vardır. Kompleks ve karşılıklı bir simbiyoz, konakçı ile bağırsak mikrobiyatası arasındaki ilişkiyi düzenler.

Probiyotiklerin hiç bir zarara neden olmadığı ve konak için faydalı olduğuna inanılan canlı organizmalar olduğu düşünülmektedir. Değişik bağırsak mikrobiyotiklerinden ve bağırsak inflamasyon bağışıklığından etkilenen İBS patogenezi nedeni olarak moleküler mekanizmalarmevcuttur.

Bu makalede bağırsak mikrobiyatası, probiyotikler ve İBS arasındaki  klinik araştırmaların sonuçları değerlendirilmiş olup bilime katkıda bulunmasıamaçlanmıştır.

Keywords

• Mikrobiyata,probiyotikler,irritable bağırsak sendromu(İBS)

References

1. Kaynaklar: 1. American College of Gastroenterology Task Force on Irritable Bowel Syndrome, Brandt LJ, Chey WD, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104 Suppl 1:S1.
2. 2. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10:712.
3. 3. American College of Gastroenterology Task Force on Irritable Bowel Syndrome, Brandt LJ, Chey WD, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104 Suppl 1:S1.)
4. 4. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006;130:1480-1491.
5. 5. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108-2131.
6. 6. Ohman L, Simrén M. New insights into the pathogenesis and pathophysiology of irritable bowel syndrome. Dig Liver Dis 2007;39:201- 215.
7. 7. Ohman L, Simrén M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010;7:163-173.
8. 8. Kassinen A, Krogius-Kurikka L, Mäkivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007;133:24-33.

9. 9. Ringel Y, Carroll IM. Alterations in the intestinal microbiota and functional bowel symptoms. Gastrointest Endosc Clin N Am 2009; 19:141-150, vii.
10. 10. Salonen A, de Vos WM, Palva A. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. Microbiology 2010;156(Pt 11):3205-3215.
11. 11. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 2014; 146:1489.
12. 12. Mohamadzadeh M, Pfeiler EA, Brown JB, et al. Regulation of induced colonic inflammation by Lactobacillus acidophilus deficient in lipoteichoic acid. Proc Natl Acad Sci U S A 2011; 108 Suppl 1:4623
13. 13. Thomas CM, Versalovic J. Probiotics-host communication: Modulation of signaling pathways in the intestine. Gut Microbes 2010;1: 148-163.
14. 14. Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2006;18:CD004826.
15. 15. Hill DA, Artis D. Intestinal bacteria and the regulation of immune cell homeostasis. Annu Rev Immunol 2010;28:623-667.
16. 16. Reid G, Younes JA, Van der Mei HC, Gloor GB, Knight R,Busscher HJ. Microbiota restoration: natural and supplemented recovery of human microbial communities. Nat Rev Microbiol 2011;9:27-38.
17. 17. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364:22-32.
18. 18. Quigley EM. Bacterial flora in irritable bowel syndrome: role in pathophysiology, implications for management. J Dig Dis 2007;8:2-7.
19. 19. Si JM, Yu YC, Fan YJ, Chen SJ. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol 2004;10:1802-1805.
20. 20. Zhang Z, Hinrichs DJ, Lu H, et al. After interleukin-12p40, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease? Int Immunopharmacol. 2007;7:409 – 416.
21. 21. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008;14: 2650-2661.
22. 22. Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 2009;9:15
23. 23. Brenner DM, Moeller M, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2009;104:1033-1049.
24. 24. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541-551.
25. 25. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006;101:1581-1590.
26. 26. Shin HY, Song YS, Kim HM, Shin TY. Inhibitory effect of inflammatory cytokines production from activated mast cells by Gamisopoonghwanghyul-tang. Immunopharmacol Immunotoxicol 2004;26:587-596.
27. 27. Kajander K, Hatakka K, Poussa T, Färkkilä M, Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 2005;22:387-394.